Navigation Links
Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
Date:2/6/2008

preceding items and other tax events (see note (h) for details); and

results of discontinued operations.

(c) Reported results in 2007 include $1.2 primarily for charges for the

sale of inventories revalued at the date of acquisition. Reported

results in 2006 include $74.1 of charges for the sale of inventories

revalued at the date of acquisition and $0.3 of accelerated

depreciation on manufacturing assets abandoned due to facility

consolidations.

(d) Reported results in 2007 and 2006 include restructuring and other

costs, net, consisting principally of severance, abandoned facility

and other expenses of real estate consolidation, net of

net gains in 2006 on the sale of product lines and abandoned

facilities. Reported results in 2006 also include $15.2 of charges for

in-process research and development associated with the

Fisher merger.

(e) Reported results in 2006 include a charge for the acceleration of

equity-based compensation expense due to a change in control.

(f) Reported results in 2006 include $0.9 of cost associated with the

early termination of debt/credit facilities in interest expense.

(g) Reported results in 2007 included an $8.9 loss from an other than

temporary decline in the fair market value of an available-for-sale

investment and a $4.5 currency transaction gain associated with an

intercompany financing transaction.

(h) Reported provision for income taxes includes i) $62.2 and $80.6 of

incremental tax benefit in 2007 and 2006, respectively, for the pre-

tax reconciling items between GAAP and adjusted net

income; and ii) in 2007, $11.1 of incremental tax benefit from

adjusting the company's deferred tax balances as a result of newly

enacted tax rates, primarily in Canada.

(i) Cons
'/>"/>

SOURCE Thermo Fisher Scientific Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related biology technology :

1. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
2. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
3. Thermo Fisher Scientific to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. Thermo Fisher Scientific to Present at the 26th Annual JPMorgan Healthcare Conference
5. Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack
6. Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing
7. MIT: Thermoelectric materials are 1 key to energy savings
8. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
9. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
10. Thermo Fisher Scientific to Expand Manufacturing Operation for Single-Use Bioprocessing Containers
11. Thermo Fisher Scientific Acquires Leader in Micro-Volume Spectrophotometers, NanoDrop Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Poway, CA (PRWEB) , ... August 27, 2015 ... ... a unique opportunity for venture capital funds, investment firms and animal health companies ... the Forum have raised $160 million. Several have also received licensing agreements or ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
(Date:8/27/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its results ... complete second quarter financial statements and MD&A have been filed on ... per shareThree-months ended , Six -months endedJune 30 , June 30 ... 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 , ...
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... 30 ITGI Medical,Ltd. (TASE: ITGI) a company ... tissue covered stents,announced that its second heterologous tissue ... AneuGraft(R) is a stent 100% covered with a ... coronary blood vessel wall and its,lumen. It is ...
... (Amex:,ULU) today announced that it has filed a ... Administration (FDA) for Altrazeal(TM) Silver., Preclinical studies ... healing rates in numerous porcine wound models have ... toxicology and,in vitro bacteria inhibition studies Altrazeal(TM) Silver ...
... named Robert P. Hammer, Ph.D., director of chemical development. , ... ... Peptide, LLC (NEP), has named Robert P. Hammer, Ph.D., director of ... University (LSU), where he was the William A. Pryor professor of ...
Cached Biology Technology:ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels 2ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver 2ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver 3New England Peptide Names Director of Chemical Development 2
(Date:8/4/2015)... (NASDAQ: AMRI ) today reported financial and operating results for ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... in EPS from royalties in the current quarter , ... are very pleased to present another strong financial quarter, with all ...
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... government for a license to perform a second field trial ... a slightly different composition, meaning that it can be converted ... manner. One of the aims of the field trial is ... Another aim will be to expose the wood from the ...
... the Institute of Molecular and Cell Biology (IMCB) have identified ... constructing stable haploid strains of Candida albicans ... made by two teams of scientists led by Prof Wang ... University of Minnesota, will enable scientists to effectively target and ...
... VA Cartilage tympanoplasty can be performed successfully in ... according to a study in the February 2013 issue ... tympanoplasty is a frequently performed procedure with varying reported ... In general, tympanic membrane repair success in children is ...
Cached Biology News:VIB applies for second poplar field trial 2A*STAR scientists solve century-old mystery by finding stable haploid strains of Candida albicans 2
Request Info...
albumin from bovine serum (BSA), fluorescein conjugate...
... Processing mini Tray (3 per pack), ... staining and blot processing.Automated staining of ... proteins and nucleic acid analysis.Prepares blots ... chromogenic detection.Programmable control of protocol, solution, ...
L1 Protein of Human Papilloma Virus Purified Anti-Viral-transformed cells clone CAMVIR-1, Isotype Mouse IgG 2a , 0.1 mg Consult technical datasheet for details....
Biology Products: